Monday, January 18, 2010
Abstract/full free access: Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada
excerpts of interest:
searchable database: eg. green tea oil, fish oil....
abstract (in research) HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in FT
"Our findings of immunoreactivity for HMGA2 may lead to a novel, useful biomarker to complement p53 in the detection of early-stage serous carcinoma."
Who is OMRF?
"Founded in 1946, OMRF is one of the nation’s oldest and most respected nonprofit biomedical research institutes. Located in Oklahoma City, OMRF fosters a worldwide reputation for excellence by following an innovative cross-disciplinary approach to medical research."
Note: this one was all over the news this past week: partial excerpt: "A new drug called dabigatran prevents more strokes with less bleeding than warfarin." Dr. Atlas says: "Dabigatran may be a game changer, but there is one thing the story didn't mention. The group that got Dabigatran had more heart attacks than those who got coumadin. Oops! This could be the real game changer from the FDA's perspective. Note it's still under review there."
abstract: The treatment of menopausal symptoms by traditional East Asian medicines: Review and perspectives
Note: abstract provides very limited information
"At its most basic level, participatory medicine means shared decision-making and deep patient engagement. Because of the rise in technology use -- as well as an increase in out-of-pocket health care expenses -- this has gone well beyond the traditional tell-me-where-it-hurts conversation between patient and doctor in the exam room....Physicians "are afraid this is something that will cost them time and money, and it will create arguments with patients," Dr. Greene said."
abstract: Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors (1994–2003)
"The prognostic impact of BMI on survival was only noted for underweight patients with serous tumors."